• Home
  • ADVAC
      • Back
      • About us
      • Course
          • Back
          • Objectives
          • Who should apply?
          • How to apply?
          • Selection criteria
          • Registration fees
          • Dates of next Courses
          • Course programme 2025
      • Scientific Committee
      • Sponsors
      • Webinars
      • Faculty 2025
      • Feature lectures
  • Apply to ADVAC
      • Back
      • Before Registering
      • Register (closed)
  • Contact
  • Login
  1. Home
  2. ADVAC
  3. Webinars
  4. details

ADVAC

  • About us
  • Course
  • Scientific Committee
  • Sponsors
  • Webinars
  • Faculty 2025
  • Feature lectures

Updates on Dengue outbreaks and vaccines

Presentations :
- Dengue epidemiology: João Bosco Siqueira Junior, Instituto de Patologia Tropical e SaudePublica, Brazil
- Dengue vaccines, GabrielaPaz-Bailey, National Center for Emerging and Zoonotic Infectious Diseases, US-CDC, PuertoRico

Read more …

Bringing an Economic Lens to Vaccine Programs

Presentations :
- The Top 5 Things to Know About the Economics of Vaccines, David Bishai, Professor & Director, School of Public Health, University of Hong Kong (20 minutes)
- Sustainability of Immunization Programs, Logan Brenzel, Consultant BMGF (20 minutes)

Read more …

Overcoming the challenges to measles and rubella elimination in south-east asia

Presentations : Prof T. Jacob John, Co-Chair of India Expert Advisory Group on Measles and Rubella Elimination.
Dr. Firdausi Qadri, Senior Scientist and Head, Mucosal Immunology and Vaccinology Unit Senior Director, Infectious Diseases Division, icddr,b, and Founder & Lead, Institute for developing Science and Health initiatives (ideSHi).

Read more …

One health: does it work? The example of Monkeypox

Presentations : Introduction by Joris Vandeputte.
Update on the animal monkeypox: Yoshi Nakazawa, US Centers for Disease Control and Prevention.
Update on the human monkeypox: Brett W. Petersen, US Centers for Disease Control and Prevention.

Read more …

  1. The power and limitations of immunobridging studies: the example of COVID-19 vaccines
  2. HPV vaccination: Prospect of moving to a one and only dose schedule
  3. Safety of COVID-19 Vaccines
  4. Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines?

Page 1 of 5

  • 1
  • 2
  • 3
  • 4
  • 5
© 2025 ADVAC -   Created by www.i-media.ch 

Privacy Policy | Cookies